Impact of fatigue on health-related quality of life and illness perception in a monocentric cohort of patients with systemic lupus erythematosus.
Adult
Case-Control Studies
Cohort Studies
Cost of Illness
Cross-Sectional Studies
Fatigue
/ etiology
Female
Fibromyalgia
/ complications
Humans
Lupus Erythematosus, Systemic
/ complications
Male
Middle Aged
Patient Reported Outcome Measures
Perception
Quality of Life
/ psychology
Severity of Illness Index
Surveys and Questionnaires
autoimmune diseases
patient perspective
systemic lupus erythematosus
Journal
RMD open
ISSN: 2056-5933
Titre abrégé: RMD Open
Pays: England
ID NLM: 101662038
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
27
10
2019
revised:
02
12
2019
accepted:
06
12
2019
entrez:
21
2
2020
pubmed:
23
2
2020
medline:
20
4
2021
Statut:
ppublish
Résumé
Fatigue is a very common and debilitating symptom in patients with systemic lupus erythematosus (SLE), even among those with a mild or inactive disease. The objective of this study is to define fatigue determinants and describe the impact of fatigue on health-related quality of life (HRQoL) and illness perception in a monocentric cohort of patients with SLE. This is a cross-sectional study. Adult patients with SLE were included. For each patient, demographics, medications, comorbidities, organ damage (Systemic Lupus International Collaborating Clinics Damage Index), active disease manifestations and Systemic Lupus Disease Activity Index scores were collected. It was evaluated if each patient met the definitions of remission and low disease activity. At enrolment, each patient completed the Short Form-36 (SF-36), Functional Assessment Chronic Illness Therapy-Fatigue (FACIT-F), Lupus Impact Tracker (LIT), Systemic Lupus Activity Questionnaire (SLAQ) and Brief Index of Lupus Damage (BILD). The FACIT-F questionnaire was also administered to a group of healthy controls. 223 patients were included (mean age 44.9±13.2 years, median disease duration 13 years). 18.2% had an active disease, 43.5% met the definition of remission on treatment, and 11.8% had a concomitant fibromyalgia. The median FACIT-F score of our cohort was significantly lower compared with that of healthy controls (40 vs 47; p<0.001). FACIT-F scores were irrespective of age, disease duration, disease activity and damage. FACIT-F score was significantly lower in patients with fibromyalgia (p<0.01). FACIT-F scores demonstrated a significant correlation with all other patient-reported outcomes: SF-36 (r=0.53-0.77), LIT (r=-0.78), SLAQ (r=-0.72) and BILD (r=-0.28). Fatigue in patients with SLE has a strong negative impact on HRQoL and patient perception of the disease burden. Fatigue seems irrespective of disease activity but significantly influenced by the presence of fibromyalgia.
Sections du résumé
BACKGROUND
Fatigue is a very common and debilitating symptom in patients with systemic lupus erythematosus (SLE), even among those with a mild or inactive disease. The objective of this study is to define fatigue determinants and describe the impact of fatigue on health-related quality of life (HRQoL) and illness perception in a monocentric cohort of patients with SLE.
METHODS
This is a cross-sectional study. Adult patients with SLE were included. For each patient, demographics, medications, comorbidities, organ damage (Systemic Lupus International Collaborating Clinics Damage Index), active disease manifestations and Systemic Lupus Disease Activity Index scores were collected. It was evaluated if each patient met the definitions of remission and low disease activity. At enrolment, each patient completed the Short Form-36 (SF-36), Functional Assessment Chronic Illness Therapy-Fatigue (FACIT-F), Lupus Impact Tracker (LIT), Systemic Lupus Activity Questionnaire (SLAQ) and Brief Index of Lupus Damage (BILD). The FACIT-F questionnaire was also administered to a group of healthy controls.
RESULTS
223 patients were included (mean age 44.9±13.2 years, median disease duration 13 years). 18.2% had an active disease, 43.5% met the definition of remission on treatment, and 11.8% had a concomitant fibromyalgia. The median FACIT-F score of our cohort was significantly lower compared with that of healthy controls (40 vs 47; p<0.001). FACIT-F scores were irrespective of age, disease duration, disease activity and damage. FACIT-F score was significantly lower in patients with fibromyalgia (p<0.01). FACIT-F scores demonstrated a significant correlation with all other patient-reported outcomes: SF-36 (r=0.53-0.77), LIT (r=-0.78), SLAQ (r=-0.72) and BILD (r=-0.28).
CONCLUSIONS
Fatigue in patients with SLE has a strong negative impact on HRQoL and patient perception of the disease burden. Fatigue seems irrespective of disease activity but significantly influenced by the presence of fibromyalgia.
Identifiants
pubmed: 32075876
pii: rmdopen-2019-001133
doi: 10.1136/rmdopen-2019-001133
pmc: PMC7046978
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
RMD Open. 2018 Nov 27;4(2):e000793
pubmed: 30564454
J Rheumatol. 2010 Feb;37(2):296-304
pubmed: 20032098
Semin Arthritis Rheum. 2017 Oct;47(2):204-215
pubmed: 28477898
Arthritis Care Res (Hoboken). 2011 Aug;63(8):1170-7
pubmed: 21584946
Arthritis Care Res (Hoboken). 2014 Jun;66(6):878-87
pubmed: 24339382
Arthritis Care Res (Hoboken). 2014 Oct;66(10):1542-50
pubmed: 24757021
J Rheumatol. 2000 Feb;27(2):373-6
pubmed: 10685799
Ann Rheum Dis. 2014 May;73(5):838-44
pubmed: 23524886
J Pain Symptom Manage. 1997 Feb;13(2):63-74
pubmed: 9095563
Lupus. 2018 Mar;27(3):454-460
pubmed: 29325492
J Rheumatol. 1997 Aug;24(8):1608-14
pubmed: 9263159
Qual Life Res. 2017 Jul;26(7):1767-1775
pubmed: 28285445
J Rheumatol. 2011 Apr;38(4):672-9
pubmed: 21239746
Rheumatology (Oxford). 2000 Nov;39(11):1249-54
pubmed: 11085805
Clin Exp Rheumatol. 2018 Jul-Aug;36(4):619-626
pubmed: 29600935
Ann Rheum Dis. 2010 Jul;69(7):1269-74
pubmed: 19892750
Curr Rheumatol Rep. 2010 Aug;12(4):250-8
pubmed: 20586000
J Rheumatol. 2008 Apr;35(4):635-42
pubmed: 18322987
J Rheumatol. 2005 Sep;32(9):1706-8
pubmed: 16142864
J Rheumatol. 2005 Sep;32(9):1699-705
pubmed: 16142863
Scand J Rheumatol. 2009 Mar-Apr;38(2):121-7
pubmed: 18991189
RMD Open. 2015 Mar 04;1(1):e000041
pubmed: 26509063
Ann Rheum Dis. 2014 Jun;73(6):958-67
pubmed: 24739325
J Rheumatol. 2010 Mar;37(3):568-73
pubmed: 20110519
Arthritis Rheum. 1990 Feb;33(2):160-72
pubmed: 2306288
J Rheumatol. 2001 Sep;28(9):1999-2007
pubmed: 11550966
J Rheumatol. 2006 Jul;33(7):1282-8
pubmed: 16758508
J Rheumatol. 1998 May;25(5):892-5
pubmed: 9598886
Lupus. 2018 Feb;27(2):190-198
pubmed: 28618891
Ann Rheum Dis. 2017 Mar;76(3):554-561
pubmed: 27884822
BMC Immunol. 2017 Mar 28;18(1):17
pubmed: 28351341
Lupus. 2018 Dec;27(14):2284-2291
pubmed: 30451638
Z Rheumatol. 2017 Dec;76(10):913-919
pubmed: 27600110
Best Pract Res Clin Rheumatol. 2005 Oct;19(5):685-708
pubmed: 16150398
Biomed Res Int. 2014;2014:704207
pubmed: 25243173
Best Pract Res Clin Rheumatol. 2013 Jun;27(3):363-75
pubmed: 24238693
Lupus. 2019 Feb;28(2):163-173
pubmed: 30580659
Ann Rheum Dis. 1999 Jun;58(6):379-81
pubmed: 10340963
Rheumatology (Oxford). 2004 Dec;43(12):1574-9
pubmed: 15353611
J Rheumatol. 2008 Nov;35(11):2152-8
pubmed: 18793004
Lupus. 2016 Oct;25(11):1190-9
pubmed: 26869353
Ann Rheum Dis. 2016 Sep;75(9):1615-21
pubmed: 26458737
Lupus. 2015 Aug;24(9):955-65
pubmed: 25697772
RMD Open. 2016 Jul 19;2(2):e000282
pubmed: 27493792
Arthritis Rheum. 2009 Sep 15;61(9):1179-86
pubmed: 19714612
J Rheumatol. 1996 Nov;23(11):1953-5
pubmed: 8923374
J Rheumatol. 2013 Nov;40(11):1865-74
pubmed: 24085548
Eur Rev Med Pharmacol Sci. 2018 Jul;22(14):4589-4597
pubmed: 30058699
Patient Educ Couns. 2005 Apr;57(1):30-8
pubmed: 15797150
Lupus. 2003;12(4):280-6
pubmed: 12729051